Economics of first-line treatment with tislelizumab in patients with nonsquamous non-small cell lung cancer.

ABSTRACT:

Objective

This study evaluates the cost-effectiveness of tislelizumab plus chemotherapy as a first-line treatment for locally advanced or metastatic (IIIB/IV) nonsquamous non-small cell lung cancer (nsq-NSCLC) in China.

Methods

A Markov model projected health outcomes and costs over a lifetime, with health states including progression-free survival, progressive disease, terminal progressive disease (TPD) and death. Data came from a Chinese phase III trial. The primary outcome was quality-adjusted life years (QALYs), with incremental cost-effectiveness ratios (ICERs) calculated. Using sensitivity analysis to confirm the robustness of the results.

Results

The base-case analysis showed that tislelizumab combined chemotherapy group had 1.06 more QALYs (3.967 QALYs VS 2.90

SUBMITTER: Wang L 

PROVIDER: S-EPMC11760221 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature